According to the suit, Gilead falsified deals to block competitor companies from producing generic versions of their HIV medications, while Gilead's brand patents on the pills’ main ingredients had expired. These agreements required partner companies to use the Gilead-branded tenofovir, even though generic versions were accessible. According to the lawsuit, individual consumers and health plans paid upwards of $30,000 per year for the brand-name HIV treatments.[1]